# Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)

> **NCT02316028** · PHASE1,PHASE2 · COMPLETED · sponsor: **Universitair Ziekenhuis Brussel** · enrollment: 11 (actual)

## Conditions studied

- Liver Metastasis
- Colorectal Cancer

## Interventions

- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT02316028
- **Lead sponsor:** Universitair Ziekenhuis Brussel
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2016-12
- **Final completion:** 2017-07
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2017-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02316028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02316028, "Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT02316028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*